Xeno­trans­plant gene ed­i­tor eGe­n­e­sis snags trans­plant ex­pert as CMO; John Tsai, Su­sanne Schaf­fert among the hard cuts made at No­var­tis

The wait­list for an or­gan trans­plant in the US ex­ceeds 100,000 peo­ple, but the bio­phar­ma world has long strug­gled to find so­lu­tions for the de­mand.

In comes the much-talked-about gene edit­ing field. A Cam­bridge, MA biotech is at­tempt­ing to use CRISPR and oth­er gene edit­ing tools to ad­dress the vi­rol­o­gy and im­munol­o­gy chal­lenges as­so­ci­at­ed with xeno­trans­plan­ta­tion, or tak­ing or­gans and cells from one species and putting them in an­oth­er. Pigs have of­ten been con­sid­ered the most like­ly route; a pa­tient re­ceived a ge­net­i­cal­ly mod­i­fied pig heart trans­plant in Jan­u­ary — the first at­tempt in decades — but trag­i­cal­ly passed two months lat­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.